SEARCH:   Advanced

Blood, 1 March 2006, Vol. 107, No. 5, pp. 2098-2100. Prepublished online as a Blood First Edition Paper on November 17, 2005; DOI 10.1182/blood-2005-08-3395. This Article Full Text (PDF) All Versions of this Article: 2005-08-3395v1 107/5/2098    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Campbell, P. J Articles by Reilly, J. T Search for Related Content PubMed PubMed Citation Articles by Campbell, P. J Articles by Reilly, J. T Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 22, 2005 Accepted October 19, 2005 The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis Peter J Campbell, Martin Griesshammer, Konstanze Dohner, Hartmut Dohner, Rajko Kusec, Hans C Hasselbalch, Thomas S Larsen, Niels Pallisgaard, Stephane Giraudier, Marie-Caroline Le Bousse-Kerdiles, Christophe Desterke, Bernadette Guerton, Brigitte Dupriez, Dominique Bordessoule, Pierre Fenaux, Jean-Jacques Kiladjian, Jean-Francois Viallard, Jean Briere, Claire N Harrison, Anthony R Green, and John T Reilly* Haematology, University of Cambridge, Cambridge, United Kingdom Department of Internal Medicine III, University of Ulm, Ulm, Germany Haematology & Clinical Chemistry, Merkur University Hospital, Zagreb, Croatia (Hrvatska) Haematology & Pathology, Odense University Hospital, Copenhagen, Denmark INSERM U362, Villejuif & Laboratoire d'Hematologie, Henri Mondor Hospital, Villejuif, France INSERM U602, Villejuif, France Hematologie Clinique, Centre Hospitalier de Lens, Lens, France Hematologie Clinique, CHRU Limoges, Limoges, France Hematologie Clinique, Hopital Avicenne, Bobigny, France Hopital du Haut-Leveque, Pessac, France Hematologie, Hopital Beaujon, Clichy, France Haematology, St Thomas's Hospital, London, United Kingdom Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom * Corresponding author; email: j.t.reilly{at}sheffield.ac.uk. Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive PCR-based methods, we genotyped 152 patients with idiopathic myelofibrosis in order to establish whether there were differences in presentation and outcome between those with and those without the mutation. V617F-positive patients had higher neutrophil and white cell counts (p=0.02) than V617F-negative patients, but other diagnostic features were comparable between the two groups. V617F-positive patients were less likely to require blood transfusion during follow-up (p=0.03). Despite this, V617F-positive patients had poorer overall survival, even after correction for confounding factors (p=0.01). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. D. Wood, E. Chen, I. J. Donaldson, S. Hattangadi, K. A. Burke, M. A. Dawson, D. Miranda-Saavedra, H. F. Lodish, A. R. Green, and B. Gottgens ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling Blood, August 27, 2009; 114(9): 1820 - 1830. [Abstract] [Full Text] [PDF] P. Guglielmelli, G. Barosi, G. Specchia, A. Rambaldi, F. Lo Coco, E. Antonioli, L. Pieri, A. Pancrazzi, V. Ponziani, F. Delaini, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele Blood, August 20, 2009; 114(8): 1477 - 1483. [Abstract] [Full Text] [PDF] F. Cervantes, B. Dupriez, A. Pereira, F. Passamonti, J. T. Reilly, E. Morra, A. M. Vannucchi, R. A. Mesa, J.-L. Demory, G. Barosi, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood, March 26, 2009; 113(13): 2895 - 2901. [Abstract] [Full Text] [PDF] P. Guglielmelli, G. Barosi, L. Pieri, E. Antonioli, A. Bosi, and A. M. Vannucchi JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis Haematologica, January 1, 2009; 94(1): 144 - 146. [Full Text] [PDF] N. Fourouclas, J. Li, D. C. Gilby, P. J. Campbell, P. A. Beer, E. M. Boyd, A. C. Goodeve, D. Bareford, C. N. Harrison, J. T. Reilly, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders Haematologica, November 1, 2008; 93(11): 1635 - 1644. [Abstract] [Full Text] [PDF] A. V. Jones, N. C.P. Cross, H. E. White, A. R. Green, and L. M. Scott Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis Haematologica, October 1, 2008; 93(10): 1560 - 1564. [Abstract] [Full Text] [PDF] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pancrazzi, V. Guerini, G. Barosi, M. Ruggeri, G. Specchia, F. Lo-Coco, F. Delaini, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia Blood, August 1, 2008; 112(3): 844 - 847. [Abstract] [Full Text] [PDF] P. A. Beer, P. J. Campbell, L. M. Scott, A. J. Bench, W. N. Erber, D. Bareford, B. S. Wilkins, J. T. Reilly, H. C. Hasselbalch, R. Bowman, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood, July 1, 2008; 112(1): 141 - 149. [Abstract] [Full Text] [PDF] A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica, January 1, 2008; 93(1): 34 - 40. [Abstract] [Full Text] [PDF] E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi, G. Longo, V. Ponziani, L. Tozzi, L. Pieri, V. Santini, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica, January 1, 2008; 93(1): 41 - 48. [Abstract] [Full Text] [PDF] A. Rambaldi, T. Barbui, and G. Barosi From Palliation to Epigenetic Therapy in Myelofibrosis Hematology, January 1, 2008; 2008(1): 83 - 91. [Abstract] [Full Text] [PDF] J. W. Vardiman Integration of Histology and Genetics in the Diagnosis and Classification of Myeloproliferative Neoplasms ASCO Educational Book, January 1, 2008; 2008(1): 339 - 345. [Abstract] [Full Text] [PDF] A. Tefferi Management of Myeloproliferative Neoplasms and the Promise of Targeted Therapy ASCO Educational Book, January 1, 2008; 2008(1): 346 - 348. [Abstract] [Full Text] [PDF] B. S. Wilkins, W. N. Erber, D. Bareford, G. Buck, K. Wheatley, C. L. East, B. Paul, C. N. Harrison, A. R. Green, and P. J. Campbell Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes Blood, January 1, 2008; 111(1): 60 - 70. [Abstract] [Full Text] [PDF] G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, M. Massa, V. Rosti, R. Campanelli, L. Villani, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis Blood, December 1, 2007; 110(12): 4030 - 4036. [Abstract] [Full Text] [PDF] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF] Q. Chen, P. Lu, A. V. Jones, N. C.P. Cross, R. T. Silver, and Y. L. Wang Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders J. Mol. Diagn., April 1, 2007; 9(2): 272 - 276. [Abstract] [Full Text] [PDF] R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood, November 15, 2006; 108(10): 3548 - 3555. [Abstract] [Full Text] [PDF] A. Tefferi Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Hematology, January 1, 2006; 2006(1): 240 - 245. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020